Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of ustekinumab in pediatric participants (Japan)
jRCT2031220186Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of ustekinumab in Crohn's disease, autoimmune colitis and psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Aug 2022; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseautoimmune colitispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2031220186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220186.